CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Peginterferon lambda alfa-1a subcutaneous injectionWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)

Name (Synonyms) Correlation
drug2176 Saline Wiki 0.38

Correlated MeSH Terms (1)

Name (Synonyms) Correlation
D007239 Infection NIH 0.06

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 Infection

This is a phase 2b prospective, randomized, single-blind, controlled trial of two weekly subcutaneous injections of lambda interferon alfa-1a versus placebo for prevention of SARS-CoV-2 infection in non-hospitalized participants at high risk for infection due to household exposure to an individual with coronavirus disease (COVID-19). The study will also evaluate the regimens participants with asymptomatic SARS-CoV-2 infection detected at study entry. All participants will be followed for up to 12 weeks.

NCT04344600 Sars-CoV2 Drug: Peginterferon lambda alfa-1a subcutaneous injection Other: Saline
MeSH:Infection

Primary Outcomes

Description: No evidence of SARS-CoV-2 infection at or before study day 28

Measure: Proportion of participants with no evidence of SARS-CoV-2 infection

Time: Up to 28 days

Description: Resolution of SARS-CoV-2 infection in the upper respiratory tract

Measure: Time (days) to no detection of SARS-CoV-2 in two upper respiratory samples

Time: Up to 14 days

No related HPO nodes (Using clinical trials)